Geron Corporation (GERN)
Geron Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Foster City, CA, US. The stock last traded at $1.60, down 1.90% on the session, giving a market capitalisation of $1.03B. On trailing twelve-month figures it carries a trailing P/E of -16.04, a net margin of -34.2%. Its beta of 0.60 implies it has historically moved less than the broad market.
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Geron Corporation is most often compared with the following Healthcare names: